Obesity and bone metabolism;Otyłość a metabolizm kości

Endokrynologia Polska

Volumn 59, Issue 3, 2008, Pages 218-223

  Holecki, Michał ^a   Zahorska Markiewicz, Barbara ^a   Wiecek, Andrzej ^a   Nieszporek, Teresa ^a   Zak Golab, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipocytokines; Fracture risk; Obesity; Osteoprotegerin; PTH; Vitamin D

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CALCIFEDIOL; ESTROGEN; INTERLEUKIN 6; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RESISTIN; VITAMIN D;

ADIPOSE TISSUE; BODY FAT; BODY MASS; BONE METABOLISM; BONE TISSUE; FRAGILITY FRACTURE; HUMAN; LEAN BODY WEIGHT; OBESITY; OSTEOLYSIS; REVIEW; RISK FACTOR;

ADIPOSE TISSUE; BONE AND BONES; FEMALE; HUMANS; MIDDLE AGED; OBESITY; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 52249091331     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Zhao LJ, Jiang H, Papasian CJ i wsp. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008; 23: 17-29.
2. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006; 2: 35-43
3. Tremollieres FA, Pouilles JM, Ribot C. Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 1993; 77: 683-686.
4. Lauritzen JB. Hip fractures: incidence, risk factors, energy absorbtion, and prevention. Bone 1996; 18: 65-75.
5. Felson DT, Zhang Y, Hannan MT i wsp. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141-1146.
6. Sabatier JP, Guaydier-Souquières G, Benmalek A i wsp. Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 1999; 9: 476-482.
7. Czerwińska E, Walicka M, Talalaj M i wsp. Bone mass in women with morbid obesity. Int J Obes 2004; 4: 4-11.
8. Goulding A, Jones IE, Taylor RW i wsp. Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy x-ray absorptiometry study. J Pediatr 2001; 139: 509-515.
9. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone density predict occurrence of osteoporotic fractures. Br Med J 1996; 312: 1254-1259.
10. Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol 1993; 138: 160-169.
11. Cifuentes M, Johnson MA, Lewis RD i wsp. Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int 2003; 14: 116-122.
12. Ravn P, Cizza G, Bjarnason NH i wsp. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999; 14: 1622-1627.
13. Haffner SM, Katz MS, Stern Dunn JF. Relationship of sex hormone binding globulin to overall adiposity and body fat distribution in biethnic population. Int J Obesity 1989; 13: 1-9.
14. Anderson DC. Sex hormone binding globulin. Clin Endocrinol 1974; 3: 69-96.
15. Murillo-Uribe A, Carranza-Lira S, Martinez-Trejo N i wsp. Influence of weight and body fat distribution on bone density in postmenopausal women. Int J Fertil Womens Med 2000; 45: 225-231.
16. O'Dea JPK, Wieland RG, Hallberg MC i wsp. Effect of dietary weight loss on sex steroid binding, sex steroids, and gonadotropins in obese postmenopausal women. J Lab Clin Med 1979; 93: 1004-1008.
17. De Laet C, Kanis JA, Odén A i wsp. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005; 16: 1330-1338.
18. Holecki M, Zahorska-Markiewicz B, Nieszporek T i wsp. Selected parameters of bone turnover in obese perimenopausal women. Ann Acad Med Siles 2006; 60:186-191.
19. Holecki M, Zahorska-Markiewicz B, Nieszporek T i wsp. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women. Endokrynol Pol - Pol J Endocrinol 2005; 3: 240-245.
20. Arunabh S, Pollack S, Yeh J i wsp. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endorinol Metab 2003,88:157-161.
21. Andersen T, Mc Nair P, Fogh-Andersen N i wsp. Increased parathyroid hormone as a consequence of changed complex binding plasma calcium in morbid obesity. Metabolism 1986; 35: 147-151.
22. Mosekilde L, Melsen I, Hessov I i wsp. Low serum levels of 1,25 dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunostomy bypass for obesity. Gut 1980; 2: 624-631.
23. McCarthy M, Thomas C. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis - implication for the impact of calcium, vitamin D and alcohol on body weight. Med Hypotheses 2003; 61: 535-542.
24. Kamycheva E, Sundsfiord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromso Study. Eur J Endocrinol 2004; 151: 167-172
25. Liel Y, Ulmer E, Shary J i wsp. Low circulating vitamin D in obesity. Calcif Tissue Int 1998; 43: 199-201.
26. Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-(OH)-D in man. J Clin Invest 1984; 74: 1540-1544.
27. Lumb GA, Mawer EB, Stanbury SW. The apparent vitamin D resistance of chronic renal failure: a study of physiology of vitamin D in man. Am J Med 1971; 50: 421-444.
28. Wortsman J, Matsuoka LY, Chen TC i wsp. Decreased bioavitability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
29. Bell NH, Epstein S, Greene A i wsp. Evidence for alteration of vitamin D endocrine system in obese subjects. J Clin Invest 1985; 76: 370-373.
30. Felson DT, Zhang Y, Hannan MT i wsp. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993; 8: 567-573.
31. Reid IR, Ames R, Evans MC i wsp. Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 1992; 75: 45-51.
32. Sabatier JP, Guaydier-Souquières G, Benmalek A i wsp. Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 1999; 9: 476-482.
33. Khosla S, Atkinson EJ, Riggs BL i wsp. Relationship between body composition and bone mass in women. J Bone Miner Res 1996; 11: 857-863.
34. Reid IR, Plank LD, Evans MC. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 1992; 75: 779-782.
35. Douchi T, Yamamoto S, Oki T i wsp. Relationship between body fat distribution and bone mineral density in premenopausal Japanese women. Obstet Gynecol 2000; 95: 722-725.
36. Riis BJ, Rødbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int 1986; 38: 318-232.
37. Janicka A, Wren TA, Sanchez MM i wsp. Fat mass is not beneficial to bone in adolescents and young adults. J Clin Endocrinol Metab 2007; 92: 143-147.
38. Zhao LJ, Liu YJ, Liu PY i wsp. Relationship of obesity with osteoporosis. J Cho Endocrinol Metab 2007, 92: 1640-1646.
39. Hsu YH, Venners SA, Herwedow HA i wsp. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 2006; 83: 146-154.
40. Castro JP, Joseph LA, Shin JJ i wsp. Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond) 2005; 2: 9.
41. Afghani A, Goran MI. Racial differences in the association of subcutaneous and visceral fat on bone mineral content in prepubertal children. Calcif Tissue Int 2006; 79: 383-388.
42. Wearing SC, Hennig EM, Byrne NM i wsp. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev 2006; 7: 239-250.
43. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigim for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 11: 905-913.
44. Yasuda H, Shima N, Nakagawa N i wsp. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPQ/OCIF inhibitsosteoclastogenesis in vitro. Endocrinology 1989; 39: 1329-1337.
45. Known BS, Wang S, Udagawa N i wsp. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone formation. FASEB J 1998; 12: 845-854.
46. Akatsu T, Murakami T, Nishikawa M i wsp. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998; 250: 229-234.
47. Fuller K, Wong B, Fox S i wsp. TRANCE is necessary and sufficient for osteoblast mediated activation ofbone resorption in osteoclast. J Exp Med 1998; 188: 997-1001.
48. Hsu H, Lacey DL, Dunstan CR i wsp. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-3545.
49. Holecki M, Zahorska-Markiewicz B, Janowska J i wsp. Osteoprotegerin - does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women. Pol J Endocrinol 2007; 58: 7-10.
50. Holecki M, Zahorska-Markiewicz B, Janowska J i wsp. The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity 2007; 15: 1925-1929.
51. Seck T, Diel I, Bismar H i wsp. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 2001; 145: 199-205.
52. Okazaki R, Inoue D, Shibata M i wsp. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology 2002; 143: 2349-2356.
53. Elefteriou F, Takeda S, Ebihara K i wsp. Serum leptin level is a regulator of bone mass. Proc Natl Arad Sci 2004; 101: 3258-3263.
54. Kontogianni MD, Dafni UG, Routsias JG i wsp. Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 2004; 19: 546-551.
55. Pasco JA, Henry MJ, Kotowicz MA i wsp. Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 2001; 86: 1884-1887.
56. Thomas T, Gori F, Khosla S i wsp. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999; 140: 1630-1638.
57. Cornish J, Callon KE, Bava U i wsp. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002; 175: 405-415.
58. Martin A, de Vittoris R, David V i wsp. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology 2005, 146: 3652-3659.
59. Ducy P, Amling M, Takeda S i wsp. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
60. Weyer C, Funahashi T, Tanaka S i wsp. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
61. Lenchik L, Register TC, Hsu PC i wsp. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003; 33: 646-651.
62. Berner HS, Lyngstadaas SP, Spahr A i wsp. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004; 35: 842-849.
63. Jürimäe J, Rembel K, Jürimäe T i wsp. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 2005; 37: 297-302.
64. Thommesen L, Stunes AK, Monjo M i wsp. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006, 99: 824-834.
65. Oh KW, Lee WY, Rhee EJ i wsp. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol 2005; 63: 131-138.
66. Rodan GA. Introduction to bone biology. Bone 1992; 13 (supl. 1): S3-S6.
67. Taguchi Y, Yamamoto M, Yamate T i wsp. Interleukin-6-type cytokines stimulate mesenchyrnal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 1998; 110: 559-574.
68. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone 2005; 37: 601-606.
69. Holecki M, Zahorska-Markiewicz B, Nieszporek T i wsp. Selected parameters of bone turnover in obese perimenopausal women. Ann Acad Med Siles 2006; 60:186-191.
70. Holecki M, Zahorska-Markiewicz B, Nieszporek T i wsp. The Influence of weight reduction during a 3-month therapy with Orlistat on bone metabolism in obese perimenopausal women. Ann Acad Med Siles 2006; 60: 273-277.
71. Tuominen JT, Impivaara O, Puukka P i wsp. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22:1196-1200.
72. Aubin JE. Bone stem cells. J Cell Biochem 1998; (supl. 30-31): 73-85.